Last reviewed · How we verify
Blinded clopidogrel
Blinded clopidogrel, marketed by the VA Office of Research and Development, is an antiplatelet agent that selectively inhibits the P2Y12 receptor to prevent platelet aggregation and reduce thrombosis risk. A key strength is its well-established mechanism of action, which is critical for managing cardiovascular events. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Blinded clopidogrel |
|---|---|
| Also known as | Plavix |
| Sponsor | VA Office of Research and Development |
| Drug class | Antiplatelet agents |
| Target | P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
Pipeline indications
Common side effects
Key clinical trials
- Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） (NA)
- Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
- Intravenous Thrombolysis With rhTNK-tPA for Acute Non-large Vessel Occlusion in Extended Time Window (PHASE4)
- Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy in Symptomatic ICAD (NA)
- Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND (PHASE3)
- Concomitant Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Moderate and Moderate-to-severe Stroke (PHASE3)
- Combining Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Large-vessel Ischemic Stroke (PHASE3)
- Tirofiban With Sequential Dual Antiplatelet Therapy in Mild Stroke (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Blinded clopidogrel CI brief — competitive landscape report
- Blinded clopidogrel updates RSS · CI watch RSS
- VA Office of Research and Development portfolio CI